Top

International Journal of Clinical Pharmacy

Published in:

01-02-2009 | Research Article

A method to include the environmental hazard in drug prescribing

Authors: Staffan Castensson, Viktoria Eriksson, Kristina Lindborg, Björn Wettermark

Published in: International Journal of Clinical Pharmacy | Issue 1/2009

Abstract

Objective Environmental classification systems for medicines have been proposed. It is important that these systems are integrated into clinical practice. Numerous studies have shown that feedback to healthcare professionals of their prescribing patterns is effective in changing behaviour. The aim of this study was to develop a method to incorporate an environmental classification for medicines in drug utilization data provided to prescribers. Drug prescribing was calculated on all pharmacy sales of medicines in ambulatory care in Stockholm, Sweden (1.9 million inhabitants) during 2006. Method Prescribing profiles were generated focusing on medicines that accounted for 90% of the volume (DU90%) of antibiotics (ATC-group J01), drugs for musculoskeletal conditions (NSAIDs, M01A), antihypertensive agents (C03, C07, C08 and C09) and antidepressants (N06A). The medicines in these 90% segments were measured as kilograms of active substance and were coded according to the classification of environmental hazard developed by Stockholm County Council and Apoteket AB. Main outcome measure Amount of pharmaceuticals dispensed (kg) and the classification of environmental hazard for the active substances accounting for the top 90% of the total amount prescribed. Results A total of 16,800 kg of antibiotics, 23,400 kg of NSAIDs, 7,700 kg of various antihypertensive substances and 1,700 kg of antidepressants had been dispensed in the region, corresponding to 2.3, 3.3, 1.1 and 0.2 kg of drug substance per square kilometre, respectively. A total of 12, 3, 13 and 9 substances accounted for 90% of the total volume of antibiotics, NSAIDs, antihypertensives and antidepressants, respectively. The proportions of potentially high environmental hazard drugs were 0, 7, 0 and 24%, respectively. Conclusion The prescribing profiles gave an easily understandable overview for the potential environmental risk and indication for where improvement could be made. The 90% profiles were easy and inexpensive to produce using available sales data and may be a valuable tool to increase the awareness of the environmental aspects among prescribing doctors.

Kümmerer K, editor. Pharmaceuticals in the environment. Sources, fate, effects and risks. 2nd ed. Berlin, Heidelberg, New York: Springer; 2004. ISBN 3-540-21342-2.

Apoteket AB (The National Corporation of Swedish Pharmacies), Stockholm County Council, Stockholm University. Environment and pharmaceuticals. Stockholm, Sweden: Apoteket AB; 2006. ISBN 91-85574-55-4. Cited 2008 Jan 18. Available from: http://www2.apoteket.se/NR/rdonlyres/FAB1EBDB-319A-4B45-95DA-CB4D863FE525/0/EnvironmentandPharmaceuticals.pdf.

Ashton D, Hilton M, Thomas KV. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. Sci Total Environ. 2004;333:167–84. doi:10.1016/j.scitotenv.2004.04.062.PubMedCrossRef

Halling-Sørensen B, Nors Nielsen S, Lanzky PF, Ingerslev F, Holten Lützhøft HC, Jørgensen SE. Occurrence, fate and effects of pharmaceutical substances in the environment-a review. Chemosphere. 1998;36:357–93. doi:10.1016/S0045-6535(97)00354-8.PubMedCrossRef

Nikolaou A, Meric S, Fatta D. Occurrence patterns of pharmaceuticals in water and wastewater environments. Anal Bioanal Chem. 2007;387:1225–34. doi:10.1007/s00216-006-1035-8.PubMedCrossRef

Zuccato E, Castiglioni S, Fanelli R, Reitano G, Bagnati R, Chiabrando C, et al. Pharmaceuticals in the environment in Italy: causes, occurrence, effects and control. Environ Sci Pollut Res Int. 2006;13:15–21. doi:10.1065/espr2006.01.004.PubMedCrossRef

Kolpin DW, Furlong ET, Meyer MT, Thurman EM, Zaugg SD, Barber LB, et al. Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999–2000: a national reconnaissance. Environ Sci Technol. 2002;36:1202–11. doi:10.1021/es011055j.PubMedCrossRef

Kümmerer K. Significance of antibiotics in the environment. J Antimicrob Chemother. 2003;52:5–7. doi:10.1093/jac/dkg293.PubMedCrossRef

Environmental Objectives Secretariat. Environmental objectives portal. Cited 2008 Jan 21. Available from: http://www.miljomal.nu/english/english.php.

10.

Miljöpåverkan från läkemedel samt kosmetiska och hygieniska produkter. Rapport från Läkemedelsverket. Augusti 2004. (Environmental impact of drugs and of cosmetic and hygienic products. Report from Swedish Medical Products Agency. August 2004.) Cited 2008 Jan 21. Available from: http://www.lakemedelsverket.se/upload/Om%20LV/publikationer/040824_miljouppdraget-rapport.pdf.

11.

Wettermark B, Godman B, Andersson K, Gustafsson LL, Haycox A, Bertele V. Recent national and regional reforms in Sweden—implications for pharmaceutical companies in Europe. Pharmacoeconomics. 2008;26:537–50.PubMed

12.

Wennmalm Å, Gunnarsson B. Public health care management of water pollution with pharmaceuticals: environmental classification and analysis of pharmaceutical residues in sewage water. Drug Inf J. 2005;39:291–7.

13.

Stockholm County Council (homepage on the Internet). About classification. Updated: 2007-07-05; cited 2008 Jan 21. Available from: http://www.janusinfo.se/imcms/servlet/GetDoc?meta_id=7239.

14.

Stockholm County Council (homepage on the Internet). Environmentally classified pharmaceuticals. Updated: 2007-12-11; cited 2008 Jan 21. Available from: http://www.janusinfo.se/imcms/servlet/GetDoc?meta_id=7238.

15.

Bero LA, Grilli R, Grimshaw JM, Harvey E, Oxman AD, Thomson MA. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. The Cochrane Effective Practice and Organization of Care Review Group. BMJ. 1998;317:465–8.PubMed

16.

Grimshaw JM, Thomas RE, MacLennan G, Fraser C, Ramsay CR, Vale L, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess. 2004;8(6):iii–iv, 1–72.

17.

Wettermark B, Pehrsson A, Jinnerot D, Bergman U. Drug utilisation 90% profiles-a useful tool for quality assessment of prescribing in primary health care in Stockholm. Pharmacoepidemiol Drug Saf. 2003;12:499–510. doi:10.1002/pds.852.PubMedCrossRef

18.

Wettermark B, Haglund K, Gustafsson LL, Persson PM, Bergman U. A study of adherence to drug recommendations by providing feedback of outpatient prescribing patterns to hospital specialists. Pharmacoepidemiol Drug Saf. 2005;14:579–88. doi:10.1002/pds.1098.PubMedCrossRef

19.

Collaboration WHO. Center for drug statistics methodology (homepage on the Internet). Guidelines for ATC classification and DDD assignment. Oslo; 2007. Cited 2008 Jan 21. Available from: www.whocc.no.

20.

Statistics Sweden. Cited 2008 June 27. Available from: http://www.h.scb.se/kommunfakta/pyramider/pyra_frame.asp?region=01.

21.

European Chemicals Bureau (ECB). Technical Guidance Document on Risk Assessment in support of Commission Directive 93/67/EEC on Risk Assessment for new notified substances and Commission Regulation (EC) No 1488/94 on Risk Assessment for existing substances and Directive 98/8/EC of the European Parliament and of the Council concerning the placing of biocidal products on the market. Part I. EUR 20418 EN/1. Luxembourg; 2003. Cited 2008 Sept 24. Available from: http://ecb.jrc.it/Documents/TECHNICAL_GUIDANCE_DOCUMENT/EDITION_2/tgdpart1_2ed.pdf.

22.

Tyle H, Larsen HS, Wedebye EB, Sijm D, Pedersen Krog T, Niemelä J. Identification of potential PBTs and vPvBs by use of QSARs. Copenhagen; 2002. Cited 2008 Sept 24. Available from: http://ecb.jrc.it/classlab/otherdocs/QSAR_PBT_final_clean.doc.

23.

World Health Organization (WHO). The rational use of drugs. WHO Report of the Conference of Experts, Nairobi. Geneva, Switzerland: World Health Organization; 1985.

24.

Bronzwaer SL, Cars O, Buchholz U, Mölstad S, Goettsch W, Veldhuijzen IK, et al. European antimicrobial resistance surveillance system. A European study on the relationship between antimicrobial use and antimicrobial resistance. Emerg Infect Dis. 2002;8:278–82.PubMedCrossRef

25.

Kaplan W, Laing R. Priority medicines for Europe and the world project. A public health approach to innovation. Geneva: WHO; 2004.

26.

Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579–87.PubMed

27.

Henry D, Lim LLY, Garcia Rodrigues LA, Perez Gutthann S, Carson JL, Griffin M, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analyses. BMJ. 1996;312:1563–6.PubMed

28.

Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2:CD002946.

29.

Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545–53. doi:10.1016/S0140-6736(05)67573-3.PubMedCrossRef

30.

Swedish Council on Technology Assessment in Health Care (SBU). Moderately elevated blood pressure. SBU report 170, 2004. Stockholm; 2004.

31.

Swedish Council on Technology Assessment in Health Care (SBU). Treatment of depression. A systematic review. Report number 166 (2 vol). 2004. ISBN 91-87890-88-7.

32.

Wettermark B. Drug utilization 90%—using aggregate drug statistics for the quality assessment of prescribing. 2004. ISBN 91-7140-048-6.

33.

EMEA. Guideline on the environmental risk assessment of medicinal products for human use EMEA/CHMP/SWP/4447/00. London; 2006. Available from: http://www.emea.europa.eu/pdfs/human/swp/444700en.pdf.

Title: A method to include the environmental hazard in drug prescribing
Authors: Staffan Castensson
Viktoria Eriksson
Kristina Lindborg
Björn Wettermark
Publication date: 01-02-2009
Publisher: Springer Netherlands
Published in: International Journal of Clinical Pharmacy / Issue 1/2009
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI: https://doi.org/10.1007/s11096-008-9260-1

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

Pharmacological differences between once daily and twice daily gentamicin dosage in newborns with suspected sepsis

Facilitators for practice change in Spanish community pharmacy

Audit of quality of perioperative antimicrobial prophylaxis

Stability of antineoplastic agents in use for home-based intravenous chemotherapy

ESCP 7th spring conference on clinical pharmacy, tackling inequalities in the delivery of pharmaceutical care, 16–19 May 2007, Edinburgh, UK

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials